Metastatic Neuroblastoma Cancer Stem Cells Exhibit Flexible Plasticity and Adaptive Stemness Signaling

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2015 Apr 19

PMID 25888913

Citations 30

Authors

Vijayabaskar Pandian

Satishkumar Ramraj

Faizan H Khan

Tasfia Azim

Natarajan Aravindan

Affiliations

Soon will be listed here.

Abstract

Introduction: High-risk neuroblastoma (HR-NB) presenting with hematogenous metastasis is one of the most difficult cancers to cure. Patient survival is poor. Aggressive tumors contain populations of rapidly proliferating clonogens that exhibit stem cell properties, cancer stem cells (CSCs). Conceptually, CSCs that evade intensive multimodal therapy dictate tumor progression, relapse/recurrence, and poor clinical outcomes. Herein, we investigated the plasticity and stem-cell related molecular response of aggressive metastatic neuroblastoma cells that fit the CSC model.

Methods: Well-characterized clones of metastatic site-derived aggressive cells (MSDACs) from a manifold of metastatic tumors of clinically translatable HR-NB were characterized for their CSC fit by examining epithelial-to-mesenchymal transition (EMT) (E-cadherin, N-Cadherin), survival (NFκB P65, p50, IκB and pIκB) and drug resistance (ABCG2) by immunoblotting; pluripotency maintenance (Nanog, SOX2) by immunofluorescence; and EMT and stemness related transcription of 93 genes by QPCR profiling. Plasticity of MSDACs under sequential alternation of culture conditions with serum and serum-free stem-cell conditions was assessed by clonal expansion (BrdU incorporation), tumorosphere formation (anchorage independent growth), EMT and stemness related transcriptome (QPCR profiling) and validated with MYC, SOX2, EGFR, NOTCH1 and CXCL2 immunoblotting.

Results: HR-NB MSDACs maintained in alternated culture conditions, serum-free stem cell medium to growth medium with serum and vice versa identified its flexible revocable plasticity characteristics. We observed signatures of stem cell-related molecular responses consistent with phenotypic conversions. Successive reintroduction to the favorable niche not only regained identical EMT, self-renewal capacity, pluripotency maintenance, and other stem cell-related signaling events, but also instigated additional events depicting aggressive adaptive plasticity.

Conclusions: Together, these results demonstrated the flexible plasticity of HR-NB MSDACs that typically fit the CSC model, and further identified the intrinsic adaptiveness of the successive phenotype switching that clarifies the heterogeneity of HR-NB. Moreover, the continuous ongoing acquisition of stem cell-related molecular rearrangements may hold the key to the switch from favorable disease to HR-NB.

Citing Articles

Leveraging Neural Crest-Derived Tumors to Identify NF1 Cancer Stem Cell Signatures.

Khan S, Alson D, Sun L, Maloney C, Sun D Cancers (Basel). 2024; 16(21).

PMID: 39518076 PMC: 11545784. DOI: 10.3390/cancers16213639.

Development and validation of a novel stemness-related prognostic model for neuroblastoma using integrated machine learning and bioinformatics analyses.

Xia Y, Wang C, Li X, Gao M, Hogg H, Tunthanathip T Transl Pediatr. 2024; 13(1):91-109.

PMID: 38323183 PMC: 10839279. DOI: 10.21037/tp-23-582.

Mesenchymal stem cell-based TRAIL delivery inhibits the metastatic state of clinical therapy-resistant progressive neuroblastoma.

Somasundaram D, Maher A, Aravindan S, Yu Z, Besch B, Aravindan N World J Pediatr. 2023; 20(3):287-293.

PMID: 38060141 DOI: 10.1007/s12519-023-00769-9.

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.

Chehelgerdi M, Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M Mol Cancer. 2023; 22(1):189.

PMID: 38017433 PMC: 10683363. DOI: 10.1186/s12943-023-01873-0.

The role of surgery in the treatment of neuroblastoma metastases at rare sites.

Scherer S, Mayer B, Dietzel M, Esser M, Warmann S, Lang P J Cancer Res Clin Oncol. 2023; 149(14):12913-12921.

PMID: 37466795 PMC: 10587098. DOI: 10.1007/s00432-023-05147-6.

References

McGinn C, Kinsella T . The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol. 1992; 19(4 Suppl 11):21-8. View

Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M . Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45(16):2835-42. DOI: 10.1016/j.ejca.2009.06.010. View

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

Khalil M, Hrabeta J, Cipro S, Stiborova M, Vicha A, Eckschlager T . Neuroblastoma stem cells - mechanisms of chemoresistance and histone deacetylase inhibitors. Neoplasma. 2012; 59(6):737-46. DOI: 10.4149/neo_2012_093. View

Park I, Zhao R, West J, Yabuuchi A, Huo H, Ince T . Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2007; 451(7175):141-6. DOI: 10.1038/nature06534. View

He K, Xu T, Xu Y, Ring A, Kahn M, Goldkorn A . Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway. Int J Cancer. 2013; 134(1):43-54. DOI: 10.1002/ijc.28341. View

Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini M . Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30(6):1076-86. DOI: 10.1002/stem.1087. View

Veeraraghavan J, Natarajan M, Herman T, Aravindan N . Low-dose γ-radiation-induced oxidative stress response in mouse brain and gut: regulation by NFκB-MnSOD cross-signaling. Mutat Res. 2010; 718(1-2):44-55. DOI: 10.1016/j.mrgentox.2010.10.006. View

Kreissman S, Seeger R, Matthay K, London W, Sposto R, Grupp S . Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013; 14(10):999-1008. PMC: 3963485. DOI: 10.1016/S1470-2045(13)70309-7. View

10.

Ross R, Spengler B . Human neuroblastoma stem cells. Semin Cancer Biol. 2006; 17(3):241-7. DOI: 10.1016/j.semcancer.2006.04.006. View

11.

Liu Q, Tang J, Cai J, Yin M, Li B . The cultivation and identification of tumor stem cells from neuroblastoma derived tumor spheres. Chin J Cancer. 2010; 29(12):1012-7. DOI: 10.5732/cjc.010.10319. View

12.

Islam M, Kanemura Y, Tajria J, Mori H, Kobayashi S, Hara M . Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci Res. 2005; 52(1):75-82. DOI: 10.1016/j.neures.2005.01.013. View

13.

Meacham C, Morrison S . Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501(7467):328-37. PMC: 4521623. DOI: 10.1038/nature12624. View

14.

Sieber-Blum M, Hu Y . Mouse epidermal neural crest stem cell (EPI-NCSC) cultures. J Vis Exp. 2008; (15). PMC: 2583017. DOI: 10.3791/772. View

15.

Smith M, Seibel N, Altekruse S, Ries L, Melbert D, OLeary M . Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28(15):2625-34. PMC: 2881732. DOI: 10.1200/JCO.2009.27.0421. View

16.

Berthold F, Hero B, BREU H, Christiansen H, Erttmann R, Gnekow A . The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol. 1996; 7(2):183-7. DOI: 10.1093/oxfordjournals.annonc.a010547. View

17.

Mahller Y, Williams J, Baird W, Mitton B, Grossheim J, Saeki Y . Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One. 2009; 4(1):e4235. PMC: 2626279. DOI: 10.1371/journal.pone.0004235. View

18.

OBrien C, Pollett A, Gallinger S, Dick J . A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2006; 445(7123):106-10. DOI: 10.1038/nature05372. View

19.

Chakrabarti L, Abou-Antoun T, Vukmanovic S, Sandler A . Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance. Front Oncol. 2012; 2:82. PMC: 3412992. DOI: 10.3389/fonc.2012.00082. View

20.

Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B . Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011; 56(4):578-83. DOI: 10.1002/pbc.22693. View